



Betamethasone Ointment Formulation

Vers 5.0	sion	Revision Date: 09.04.2021		DS Number: 342062-00009	Date of last issue: 10.10.2020 Date of first issue: 19.07.2017
SEC	CTION	1: Identification of	the	substance/mixt	ure and of the company/undertaking
1.1	Product	tidentifier			
	Trade r	name	:	Betamethasone (Dintment Formulation
1.2	Relevar	nt identified uses of t	he s	substance or mixt	ure and uses advised against
		the Sub- /Mixture	:	Pharmaceutical	
1.3	Details	of the supplier of the	sat	ety data sheet	
	Compa	ny	:	Organon & Co. 30 Hudson Stree 07302 Jersey Ci	t, 33nd floor ty, New Jersey, U.S.A
	Teleph	one	:	551-430-6000	
		address of person sible for the SDS	:	EHSSTEWARD@	⊉organon.com
1.4	Emerge	ncy telephone numb	er		

215-631-6999

SECTION 2: Hazards identification

2.1 Classification of the substance or mixture

Classification (REGULATION (EC) No 1272/2008)

Reproductive toxicity, Category 1B Specific target organ toxicity - repeated exposure, Category 1 Long-term (chronic) aquatic hazard, Cat- egory 1	H360D: May damage the unborn child.H372: Causes damage to organs through prolonged or repeated exposure.H410: Very toxic to aquatic life with long lasting effects.
--	---

2.2 Label elements

Labelling (REGULATION (EC) No 1272/2008)

Hazard pictograms	:	
Signal word	:	Danger
Hazard statements	:	H360D May damage the unborn child.H372 Causes damage to organs through prolonged or repeated exposure.H410 Very toxic to aquatic life with long lasting effects.
Precautionary statements	:	Prevention:

according to Regulation (EC) No. 1907/2006



Betamethasone Ointment Formulation

Version 5.0	Revision Date: 09.04.2021	SDS Number: 1842062-00009	Date of last issue: 10.10.2020 Date of first issue: 19.07.2017
		P264 Wash skin P273 Avoid relea	ecial instructions before use. thoroughly after handling. ase to the environment. ective gloves/ protective clothing/ eye protec- n.
		Response: P308 + P313 IF attention. P391 Collect spi	exposed or concerned: Get medical advice/

Hazardous components which must be listed on the label:

betamethasone

2.3 Other hazards

This substance/mixture contains no components considered to be either persistent, bioaccumulative and toxic (PBT), or very persistent and very bioaccumulative (vPvB) at levels of 0.1% or higher.

Ecological information: The substance/mixture does not contain components considered to have endocrine disrupting properties according to REACH Article 57(f) or Commission Delegated regulation (EU) 2017/2100 or Commission Regulation (EU) 2018/605 at levels of 0.1% or higher.

Toxicological information: The substance/mixture does not contain components considered to have endocrine disrupting properties according to REACH Article 57(f) or Commission Delegated regulation (EU) 2017/2100 or Commission Regulation (EU) 2018/605 at levels of 0.1% or higher.

SECTION 3: Composition/information on ingredients

3.2 Mixtures


Components

Chemical name	CAS-No. EC-No.	Classification	Concentration (% w/w)
	Index-No.		(70 00700)
	Registration number		
Paraffin oil	8012-95-1	Asp. Tox. 1; H304	>= 2.5 - < 10
	232-384-2	Aquatic Chronic 4; H413	
betamethasone	378-44-9 206-825-4	Acute Tox. 2; H330 Repr. 1B; H360D STOT RE 1; H372 (Pituitary gland, Im- mune system, mus- cle, thymus gland, Blood, Adrenal gland) Aquatic Chronic 1; H410	>= 0.025 - < 0.1
		M-Factor (Chronic aquatic toxicity): 1,000	

according to Regulation (EC) No. 1907/2006



Betamethasone Ointment Formulation



For explanation of abbreviations see section 16.

SECTION 4: First aid measures

4.1 Description of first aid measures					
General advice :	In the case of accident or if you feel unwell, seek medical ad- vice immediately. When symptoms persist or in all cases of doubt seek medical advice.				
Protection of first-aiders :	First Aid responders should pay attention to self-protection, and use the recommended personal protective equipment when the potential for exposure exists (see section 8).				
If inhaled :	If inhaled, remove to fresh air. Get medical attention.				
In case of skin contact :	In case of contact, immediately flush skin with soap and plenty of water. Remove contaminated clothing and shoes. Get medical attention. Wash clothing before reuse. Thoroughly clean shoes before reuse.				
In case of eye contact :	Flush eyes with water as a precaution. Get medical attention if irritation develops and persists.				
If swallowed :	If swallowed, DO NOT induce vomiting. Get medical attention. Rinse mouth thoroughly with water.				
4.2 Most important symptoms and	effects, both acute and delayed				
Risks :	May damage the unborn child. Causes damage to organs through prolonged or repeated exposure.				
4.3 Indication of any immediate medical attention and special treatment needed					
Treatment :	Treat symptomatically and supportively.				

according to Regulation (EC) No. 1907/2006



Betamethasone Ointment Formulation

Version	Revision Date:	SDS Number:	Date of last issue: 10.10.2020
5.0	09.04.2021	1842062-00009	Date of first issue: 19.07.2017

SECTION 5: Firefighting measures

5.1 Extinguishing media

Suitable extinguishing media	:	Water spray Alcohol-resistant foam Carbon dioxide (CO2) Dry chemical
Unsuitable extinguishing media	:	None known.

5.2 Special hazards arising from the substance or mixture

one opposition naear do anoning nom		
Specific hazards during fire- fighting	:	Vapours may form explosive mixtures with air. Exposure to combustion products may be a hazard to health.
Hazardous combustion prod- ucts	:	Carbon oxides
5.3 Advice for firefighters		
Special protective equipment for firefighters	:	In the event of fire, wear self-contained breathing apparatus. Use personal protective equipment.
Specific extinguishing meth- ods	:	Use extinguishing measures that are appropriate to local cir- cumstances and the surrounding environment. Use water spray to cool unopened containers. Remove undamaged containers from fire area if it is safe to do so. Evacuate area.

SECTION 6: Accidental release measures

6.1 Personal precautions, protective equipment and emergency procedures

Personal precautions	:	Use personal protective equipment. Follow safe handling advice (see section 7) and personal pro- tective equipment recommendations (see section 8).		
6.2 Environmental precautions				
Environmental precautions	:	Avoid release to the environment. Prevent further leakage or spillage if safe to do so. Retain and dispose of contaminated wash water. Local authorities should be advised if significant spillages cannot be contained.		
6.3 Methods and material for containment and cleaning up				

Methods	for cleaning up	:	Sweep up or vacuum up spillage and collect in suitable con- tainer for disposal. Local or national regulations may apply to releases and dis- posal of this material, as well as those materials and items employed in the cleanup of releases. You will need to deter-
			employed in the cleanup of releases. You will need to deter-

according to Regulation (EC) No. 1907/2006



Version 5.0	Revision Date: 09.04.2021	SDS Number: 1842062-00009	Date of last issue: 10.10.2020 Date of first issue: 19.07.2017
		Sections 13 and	ulations are applicable. I 15 of this SDS provide information regarding national requirements.
6.4 Refere	ence to other sections		
	ons: 7, 8, 11, 12 and 13.		
SECTION	7: Handling and sto	orade	
		Jiage	
7.1 Preca	utions for safe handlin	Ig	
Tech	nical measures		g measures under EXPOSURE RSONAL PROTECTION section.
Local	/Total ventilation	: If sufficient vent	ilation is unavailable, use with local exhaust
Advic	e on safe handling	ventilation. Do not get on sl Do not breathe Do not swallow. Avoid contact w	dust, fume, gas, mist, vapours or spray.
Hygie	ene measures	 Wash skin thoro Handle in accor practice, based sessment Keep container Do not eat, drint Take care to pre environment. If exposure to cl flushing systems place. When us nated clothing b The effective op engineering con appropriate deg 	bughly after handling. dance with good industrial hygiene and safety on the results of the workplace exposure as- tightly closed. K or smoke when using this product. event spills, waste and minimize release to the memical is likely during typical use, provide eye is and safety showers close to the working ing do not eat, drink or smoke. Wash contami- efore re-use. veration of a facility should include review of trols, proper personal protective equipment, owning and decontamination procedures, ne monitoring, medical surveillance and the
7.2 Condi	tions for safe storage,	including any incor	npatibilities
	irements for storage and containers		y labelled containers. Store locked up. Keep tore in accordance with the particular national
Advic	e on common storage	: Do not store wit Strong oxidizing Organic peroxic Explosives Gases	
7 3 Snaci	fic end use(s)		
-	ific use(s)	: No data availab	le

according to Regulation (EC) No. 1907/2006



Betamethasone Ointment Formulation

Version	Revision Date:	SDS Number:	Date of last issue: 10.10.2020
5.0	09.04.2021	1842062-00009	Date of first issue: 19.07.2017

SECTION 8: Exposure controls/personal protection

8.1 Control parameters

Occupational Exposure Limits

Components	CAS-No.	Value type (Form of exposure)	Control parameters	Basis
Petrolatum	8009-03-8	OELV - 8 hrs (TWA) (inhalable fraction)	5 mg/m3	IE OEL
			ecific short-term exposure lim posure limit value should be	
Paraffin oil	8012-95-1	OELV - 8 hrs (TWA) (inhalable fraction)	5 mg/m3	IE OEL
betamethasone	betamethasone 378-44-9		1 μg/m3 (OEB 4)	Internal
	Further inform	nation: Skin		
		Wipe limit	10 μg/100 cm ²	Internal

Derived No Effect Level (DNEL) according to Regulation (EC) No. 1907/2006:

Substance name	End Use	Exposure routes	Potential health ef- fects	Value
Paraffin oil	Workers	Inhalation	Long-term systemic effects	5 mg/m3
	Workers	Inhalation	Short-term exposure	5 mg/m3
	Workers	Inhalation	Long-term local ef- fects	5 mg/m3
	Workers	Inhalation	Acute local effects	5 mg/m3

Predicted No Effect Concentration (PNEC) according to Regulation (EC) No. 1907/2006:

Substance name	Environmental Compartment	Value
Petrolatum	Oral (Secondary Poisoning)	9.33 mg/kg food

8.2 Exposure controls

Engineering measures

Containment technologies suitable for controlling compounds are required to control at source and to prevent migration of the compound to uncontrolled areas (e.g., vacuum conveying from a closed system, packout head with inflatable seal from stationary container, ventilated enclosure, etc.).

All engineering controls should be implemented by facility design and operated in accordance with GMP principles to protect products, workers, and the environment.

Essentially no open handling permitted. Use closed processing systems or containment technologies.

Personal protective equipment

Eye protection	:	Wear safety glasses with side shields or goggles. If the work environment or activity involves dusty conditions, mists or aerosols, wear the appropriate goggles. Wear a faceshield or other full face protection if there is a
		potential for direct contact to the face with dusts, mists, or aerosols.

according to Regulation (EC) No. 1907/2006



Betamethasone Ointment Formulation

Version 5.0	Revision Date: 09.04.2021		DS Number: 342062-00009	Date of last issue: 10.10.2020 Date of first issue: 19.07.2017	
Hand J	protection				
Ма	terial	:	Chemical-resistar	nt gloves	
Remarks Skin and body protection		:	 Consider double gloving. Work uniform or laboratory coat. Additional body garments should be used based upon the task being performed (e.g., sleevelets, apron, gauntlets, dis- posable suits) to avoid exposed skin surfaces. Use appropriate degowning techniques to remove potentially contaminated clothing. 		
Respiratory protection		:	If adequate local exhaust ventilation is not available or expo- sure assessment demonstrates exposures outside the rec- ommended guidelines, use respiratory protection. Equipment should conform to I.S. EN 14387		
Filt	er type	:	Combined particu	lates and organic vapour type (A-P)	

SECTION 9: Physical and chemical properties

9.1 Information on basic physical and chemical properties

Physical state	:	ointment
Colour	:	No data available
Odour	:	No data available
Odour Threshold	:	No data available
Melting point/freezing point	:	No data available
Initial boiling point and boiling range	:	No data available
Flammability (solid, gas)	:	Not classified as a flammability hazard
Flammability (liquids)	:	Not applicable
Upper explosion limit / Upper flammability limit	:	No data available
Lower explosion limit / Lower flammability limit	:	No data available
Flash point	:	> 93.3 °C
Auto-ignition temperature	:	No data available
Decomposition temperature Decomposition tempera-	:	No data available
ture	•	
рН	:	No data available
Viscosity Viscosity, kinematic	:	Not applicable
Solubility(ies) Water solubility	:	No data available

according to Regulation (EC) No. 1907/2006



Betamethasone Ointment Formulation

Partition coefficient: n- octanol/water:Not applicableVapour pressure:No data availableRelative density:No data availableDensity:No data availableRelative vapour density:Not applicableParticle characteristics Particle size:Not applicable9.2 Other information:Not availableExplosives:Not explosiveOxidizing properties:Not explosiveEvaporation rate:Not applicable	Version 5.0	Revision Date: 09.04.2021	SDS Number: 1842062-00009	Date of last issue: 10.10.2020 Date of first issue: 19.07.2017
Particle characteristics Particle size : No data available 9.2 Other information Explosives : Not explosive Oxidizing properties : Not explosive	octan Vapo Relat Dens	ol/water ur pressure ive density ity	 No data avail No data avail No data avail 	able able able
Explosives: Not explosiveOxidizing properties: The substance or mixture is not classified as oxidizing.	Partic	le characteristics		
Oxidizing properties : The substance or mixture is not classified as oxidizing.	9.2 Other	information		
	Explo	sives	: Not explosive	
Evaporation rate : Not applicable	Oxidi	zing properties	: The substance	e or mixture is not classified as oxidizing.
	Evap	oration rate	: Not applicable	e

SECTION 10: Stability and reactivity

10.1 Reactivity		
Not classified as a reactivity	haza	rd.
10.2 Chemical stability		
Stable under normal conditio	ns.	
10.3 Possibility of hazardous re	actio	ons
Hazardous reactions	:	Vapours may form explosive mixture with air. Can react with strong oxidizing agents.
10.4 Conditions to avoid		
Conditions to avoid	:	None known.
10.5 Incompatible materials		
Materials to avoid	:	Oxidizing agents
10.6 Hazardous decomposition No hazardous decompositior	-	
SECTION 11: Toxicological i	nfor	mation

11.1 Information on hazard classes as defined in Regulation (EC) No 1272/2008

Information on likely routes of	:	Skin contact
exposure		Ingestion
		Eye contact

according to Regulation (EC) No. 1907/2006



Betamethasone Ointment Formulation

ersion 0	Revision Date: 09.04.2021	SDS Number: 1842062-00009	Date of last issue: 10.10.2020 Date of first issue: 19.07.2017
Acute	e toxicity		
Not cl	assified based on ava	ailable information.	
Comp	oonents:		
Paraf	fin oil:		
Acute	oral toxicity	: LD50 (Rat): >	5,000 mg/kg
Acute	dermal toxicity		: > 2,000 mg/kg The substance or mixture has no acute dermal
betan	nethasone:		
Acute	oral toxicity	: LD50 (Rat): >	5,000 mg/kg
		LD50 (Mouse): > 4,500 mg/kg
Acute	inhalation toxicity	: LC50 (Rat): 0 Exposure time	
-	corrosion/irritation assified based on ava	ailable information.	
Comp	oonents:		
Paraf	fin oil:		
Speci Resul		: Rabbit : No skin irritati	on
betan	nethasone:		
Speci		: Rabbit	
Resul	t	: Mild skin irrita	tion
Serio	us eye damage/eye	irritation	
Not cl	assified based on ava	ailable information.	
Comp	oonents:		
Paraf	fin oil:		
Speci		: Rabbit	
Resul	τ	: No eye irritation	on
betan	nethasone:		
betan Speci Resul	es	: Rabbit : No eye irritatio	

Skin sensitisation

Not classified based on available information.

according to Regulation (EC) No. 1907/2006



/ersion 5.0	Revision Date: 09.04.2021		9S Number: 42062-00009	Date of last issue: 10.10.2020 Date of first issue: 19.07.2017
Respi	iratory sensitisation			
Not cl	assified based on availa	ble	information.	
Comp	oonents:			
betam	nethasone:			
	sure routes	:	Dermal	
Specie Resul		:	Guinea pig Weak sensitizer	
	cell mutagenicity			
Not cl	assified based on availa	ble	information.	
Comp	oonents:			
	nethasone:			
Genot	toxicity in vitro	:	Test Type: Bacter Result: negative	ial reverse mutation assay (AMES)
			Test Type: In vitro Result: negative	mammalian cell gene mutation test
			Test Type: Chrom Result: positive	osome aberration test in vitro
Genot	toxicity in vivo	:	Test Type: Mamm cytogenetic assay Species: Mouse Application Route Result: equivocal	
Germ sessm	cell mutagenicity- As- nent	:	Weight of evidenc cell mutagen.	e does not support classification as a germ
	nogenicity			
	assified based on availa	ble	information.	
-	oductive toxicity			
-	lamage the unborn child	•		
	oonents:			
Щ	nethasone:			
Effects	s on foetal develop-	:		: Intramuscular oxicity: LOAEL: 0.05 mg/kg body weight y, Malformations were observed.
				: Subcutaneous oxicity: LOAEL: 0.42 mg/kg body weight ions were observed.
II			Species: Mouse	
			10 / 18	

according to Regulation (EC) No. 1907/2006



Version 5.0	Revision Date: 09.04.2021	-	DS Number: 42062-00009	Date of last issue: 10.10.2020 Date of first issue: 19.07.2017
				e: Intramuscular oxicity: LOAEL: 1 mg/kg body weight tions were observed.
Repr sessi	oductive toxicity - As- ment	:	Clear evidence of animal experimer	adverse effects on development, based on tts.
	T - single exposure classified based on availa	able	information.	
	T - repeated exposure ses damage to organs th	rouc	ah prolonaed or rep	eated exposure.
<u>Com</u>	ponents:			
UL	methasone: et Organs	:	, ,	nmune system, muscle, thymus gland, Blood,
Asse	ssment	:	Adrenal gland Causes damage exposure.	to organs through prolonged or repeated
Repe	eated dose toxicity			
Com	ponents:			
	ffin oil:			
Spec LOA		:	Rat, female 161 mg/kg	
_	cation Route	:	Ingestion	
Expo	sure time	:	90 Days	
beta	methasone:			
Spec		:	Rabbit	
LOAI	EL cation Route	:	0.05 % Skin contact	
Expo	sure time	:	10 - 30 d	
Targ	et Organs	:	Pituitary gland, In	nmune system, muscle
Spec	ies	:	Rat	
LOA		:	0.05 %	
	cation Route	:	Skin contact 8 Weeks	
	et Organs	:	thymus gland	
Spec		:	Mouse	
LOA		:	0.1 %	
Appii Expo	cation Route		Skin contact 8 Weeks	
	et Organs	:	thymus gland	
Spec		:	Dog	
LOA	EL	:	0.05 mg/kg	
Appli	cation Route	:	Oral	

according to Regulation (EC) No. 1907/2006



Betamethasone Ointment Formulation

Version	Revision Date:	SDS Number:	Date of last issue: 10.10.2020
5.0	09.04.2021	1842062-00009	Date of first issue: 19.07.2017
Expos	sure time	: 28 d	s gland, Adrenal gland
Targe	t Organs	: Blood, thymus	

Aspiration toxicity

Not classified based on available information.

Components:

Paraffin oil:

The substance or mixture is known to cause human aspiration toxicity hazards or has to be re-garded as if it causes a human aspiration toxicity hazard.

11.2 Information on other hazards

Endocrine disrupting properties

Product:

Assessment	: The substance/mixture does not contain components consid- ered to have endocrine disrupting properties according to REACH Article 57(f) or Commission Delegated regulation (EU) 2017/2100 or Commission Regulation (EU) 2018/605 at levels of 0.1% or higher.
------------	---

Experience with human exposure

Components: betamethasone: Inhalation : Target Organs: Adrenal gland Skin contact

	0 0		0	
:	Symptoms:	Redness,	pruritis,	Irritation

SECTION 12: Ecological information

12.1 Toxicity

Components:

Paraffin oil:		
Toxicity to fish	:	LL50 (Scophthalmus maximus (turbot)): > 100 mg/l Exposure time: 96 h Test substance: Water Accommodated Fraction Remarks: Based on data from similar materials
Toxicity to daphnia and other aquatic invertebrates	:	EL50 (Acartia tonsa): > 100 mg/l Exposure time: 48 h Test substance: Water Accommodated Fraction Remarks: Based on data from similar materials
Toxicity to algae/aquatic plants	:	EL50 (Skeletonema costatum (marine diatom)): > 100 mg/l Exposure time: 72 h Test substance: Water Accommodated Fraction Remarks: Based on data from similar materials

according to Regulation (EC) No. 1907/2006



Versi 5.0	on	Revision Date: 09.04.2021	-	9S Number: 42062-00009	Date of last issue: 10.10.2020 Date of first issue: 19.07.2017
				Exposure time: 72 Test substance: V	nema costatum (marine diatom)): > 1 mg/l 2 h Vater Accommodated Fraction on data from similar materials
	betame	ethasone:			
		to daphnia and other invertebrates	:	EC50 (Americamy Exposure time: 96	
	Toxicity plants	v to algae/aquatic	:	mg/l Exposure time: 72 Method: OECD To	
				mg/l Exposure time: 72 Method: OECD To	
	Toxicity icity)	v to fish (Chronic tox-	:	NOEC: 0.052 mg/ Exposure time: 32 Species: Pimepha Method: OECD To	2 d ales promelas (fathead minnow)
				NOEC: 0.07 µg/l Exposure time: 2' Species: Oryzias Method: OECD Te	latipes (Japanese medaka)
a		v to daphnia and other invertebrates (Chron- ity)	:	NOEC: 8 mg/l Exposure time: 2 ⁴ Species: Daphnia Method: OECD T	magna (Water flea)
	M-Fact toxicity	or (Chronic aquatic)	:	1,000	
		tence and degradabil a available	ity		
12.3 Bioaccumulative potential					
	Compo	onents:			
- ïi	Paraffi Partitio octanol	n coefficient: n-	:	log Pow: > 4 Remarks: Calcula	tion
Π		e thasone: n coefficient: n- /water	:	log Pow: 2.11	

according to Regulation (EC) No. 1907/2006



Betamethasone Ointment Formulation

Version	Revision Date:	SDS Number:	Date of last issue: 10.10.2020
5.0	09.04.2021	1842062-00009	Date of first issue: 19.07.2017

12.4 Mobility in soil

No data available

12.5 Results of PBT and vPvB assessment

Product:

Assessment : This substance/mixture contains no components considered to be either persistent, bioaccumulative and toxic (PBT), or very persistent and very bioaccumulative (vPvB) at levels of 0.1% or higher.

12.6 Endocrine disrupting properties

Product:

: The substance/mixture does not contain components consid-Assessment ered to have endocrine disrupting properties according to REACH Article 57(f) or Commission Delegated regulation (EU) 2017/2100 or Commission Regulation (EU) 2018/605 at levels of 0.1% or higher.

12.7 Other adverse effects

No data available

SECTION 13: Disposal considerations

13.1 Waste treatment methods

Product	:	Dispose of in accordance with local regulations. According to the European Waste Catalogue, Waste Codes are not product specific, but application specific. Waste codes should be assigned by the user, preferably in discussion with the waste disposal authorities.
Contaminated packaging	:	Empty containers should be taken to an approved waste han- dling site for recycling or disposal. If not otherwise specified: Dispose of as unused product.

SECTION 14: Transport information

14.1 UN number or ID number

ADN	:	UN 3077
ADR	:	UN 3077
RID	:	UN 3077
IMDG	:	UN 3077
ΙΑΤΑ	:	UN 3077

1

14.2 UN proper shipping name

ENVIRONMENTALLY HAZARDOUS SUBSTANCE, SOLID, N.O.S.

(betamethasone)



according to Regulation (EC) No. 1907/2006

Betamethasone Ointment Formulation

Version 5.0	Revision Date: 09.04.2021	SDS Number:Date of last issue: 10.10.2020842062-00009Date of first issue: 19.07.2017			
ADR		ENVIRONMENTALLY HAZARDOUS SUBSTANCE N.O.S. (betamethasone)	, SOLID,		
RID		ENVIRONMENTALLY HAZARDOUS SUBSTANCE N.O.S. (betamethasone)	, SOLID,		
IMDG	3	ENVIRONMENTALLY HAZARDOUS SUBSTANCE N.O.S. (betamethasone)	, SOLID,		
ΙΑΤΑ		Environmentally hazardous substance, solid, n.o.s. (betamethasone)			
14.3 Tran	sport hazard class(es)				
ADN		9			
ADR		9			
RID		9			
IMDG	6	9			
ΙΑΤΑ		9			
14.4 Pack	ing group				
Class	ing group sification Code rd Identification Number Is	: III : M7 : 90 : 9			
Class Haza Label	ing group sification Code rd Identification Number Is el restriction code	: III : M7 : 90 : 9 : (-)			
Class	ing group sification Code rd Identification Number Is	: III M7 : 90 : 9			
Label	ing group	: III : 9 : F-A, S-F			
Packi aircra Packi	ing instruction (LQ) ing group Is	956 Y956 III Miscellaneous			

IATA (Passenger)

according to Regulation (EC) No. 1907/2006



Betamethasone Ointment Formulation

Vers 5.0	sion	Revision Date: 09.04.2021		DS Number: 42062-00009	Date of last issue: 10.10.2020 Date of first issue: 19.07.2017
	ger airo Packin	g instruction (LQ) g group	:	956 Y956 III Miscellaneous	
14.5	Enviro	onmental hazards			
	ADN Enviror	nmentally hazardous	:	yes	
	ADR Enviror	nmentally hazardous	:	yes	
	RID Enviror	nmentally hazardous	:	yes	
	IMDG Marine	pollutant	:	yes	
		Passenger) nmentally hazardous	:	yes	
	•	Cargo) nmentally hazardous	:	yes	

14.6 Special precautions for user

The transport classification(s) provided herein are for informational purposes only, and solely based upon the properties of the unpackaged material as it is described within this Safety Data Sheet. Transportation classifications may vary by mode of transportation, package sizes, and variations in regional or country regulations.

14.7 Maritime transport in bulk according to IMO instruments

Remarks

: Not applicable for product as supplied.

SECTION 15: Regulatory information

15.1 Safety, health and environmental regulations/legislation specific for the substance or mixture

REACH - Restrictions on the manufacture, placing on the market and use of certain dangerous substances, preparations and articles (Annex XVII)	:	Not applicable	
REACH - Candidate List of Substances of Very High	:	Not applicable	
Concern for Authorisation (Article 59).			
REACH - List of substances subject to authorisation	:	Not applicable	
(Annex XIV)			
Regulation (EC) No 1005/2009 on substances that de-	:	Not applicable	
plete the ozone layer			
Regulation (EU) 2019/1021 on persistent organic pollu-	:	Not applicable	
tants (recast)			
Regulation (EC) No 649/2012 of the European Parlia- ment and the Council concerning the export and import of dangerous chemicals	:	Not applicable	
•		t and of the Council	on the control of
Seveso III: Directive 2012/18/EU of the European Parliam major-accident hazards involving dangerous substances.			
		Quantity 1	Quantity 2

E1	ENVIRONMENTAL	Quantity 1 100 t	Quantity 2 200 t



according to Regulation (EC) No. 1907/2006

Betamethasone Ointment Formulation

Version 5.0	Revision Date: 09.04.2021	SDS Number: 1842062-00009	Date of last issue: 10.10.2020 Date of first issue: 19.07.2017		
		HAZARDS			
Take where Take	e applicable.	EC on the protection	nity protection or stricter national regulations, of young people at work or stricter national		
The of AICS	• •	duct are reported in : not determined	n the following inventories:		
DSL		: not determined	not determined		
IECS	C	: not determined	not determined		
	N 16: Other information	: Items where ch	anges have been made to the previous version in the body of this document by two vertical		
Full t H304 H330 H360 H372 H410 H413) D 2	 Fatal if inhaled. May damage th Causes damage exposure. Very toxic to aquestion 	wallowed and enters airways. e unborn child. e to organs through prolonged or repeated uatic life with long lasting effects. lasting harmful effects to aquatic life.		
Full t	Full text of other abbreviations				
	e Tox. tic Chronic	: Acute toxicity : Long-term (chro : Aspiration haza	onic) aquatic hazard		

ADN - European Agreement concerning the International Carriage of Dangerous Goods by Inland Waterways; ADR - European Agreement concerning the International Carriage of Dangerous Goods by Road; AIIC - Australian Inventory of Industrial Chemicals; ASTM - American Society for the Testing of Materials; bw - Body weight; CLP - Classification Labelling Packaging Regulation; Regulation (EC) No 1272/2008; CMR - Carcinogen, Mutagen or Reproductive Toxicant; DIN - Standard of the German Institute for Standardisation; DSL - Domestic Substances List (Canada); ECHA - European Chemicals Agency; EC-Number - European Community number; ECx - Concentration associated with x% response; ELx - Loading rate associated with x% response; EmS - Emergency Schedule; ENCS - Existing and New Chemical Substances (Japan); ErCx - Concentration associated with x% growth rate response; GHS - Globally Harmonized System; GLP -



Betamethasone Ointment Formulation

Version	Revision Date:	SDS Number:	Date of last issue: 10.10.2020
5.0	09.04.2021	1842062-00009	Date of first issue: 19.07.2017

Good Laboratory Practice; IARC - International Agency for Research on Cancer; IATA - International Air Transport Association; IBC - International Code for the Construction and Equipment of Ships carrying Dangerous Chemicals in Bulk; IC50 - Half maximal inhibitory concentration; ICAO - International Civil Aviation Organization; IECSC - Inventory of Existing Chemical Substances in China; IMDG - International Maritime Dangerous Goods; IMO - International Maritime Organization; ISHL - Industrial Safety and Health Law (Japan); ISO - International Organisation for Standardization; KECI - Korea Existing Chemicals Inventory; LC50 - Lethal Concentration to 50 % of a test population; LD50 - Lethal Dose to 50% of a test population (Median Lethal Dose); MARPOL -International Convention for the Prevention of Pollution from Ships; n.o.s. - Not Otherwise Specified; NO(A)EC - No Observed (Adverse) Effect Concentration; NO(A)EL - No Observed (Adverse) Effect Level; NOELR - No Observable Effect Loading Rate; NZIoC - New Zealand Inventory of Chemicals; OECD - Organization for Economic Co-operation and Development; OPPTS - Office of Chemical Safety and Pollution Prevention; PBT - Persistent, Bioaccumulative and Toxic substance; PICCS - Philippines Inventory of Chemicals and Chemical Substances; (Q)SAR - (Quantitative) Structure Activity Relationship; REACH - Regulation (EC) No 1907/2006 of the European Parliament and of the Council concerning the Registration, Evaluation, Authorisation and Restriction of Chemicals; RID - Regulations concerning the International Carriage of Dangerous Goods by Rail; SADT - Self-Accelerating Decomposition Temperature; SDS - Safety Data Sheet; SVHC - Substance of Very High Concern; TCSI - Taiwan Chemical Substance Inventory; TRGS -Technical Rule for Hazardous Substances; TSCA - Toxic Substances Control Act (United States); UN - United Nations; vPvB - Very Persistent and Very Bioaccumulative

Further information

Sources of key data used to	:	Internal technical data, data from raw material SDSs, OECD
compile the Safety Data		eChem Portal search results and European Chemicals Agen-
Sheet		cy, http://echa.europa.eu/

Classification of the mixture:		Classification procedure:	
Repr. 1B	H360D	Calculation method	
STOT RE 1	H372	Calculation method	
Aquatic Chronic 1	H410	Calculation method	

Items where changes have been made to the previous version are highlighted in the body of this document by two vertical lines.

The information provided in this Safety Data Sheet is correct to the best of our knowledge, information and belief at the date of its publication. The information is designed only as a guidance for safe handling, use, processing, storage, transportation, disposal and release and shall not be considered a warranty or quality specification of any type. The information provided relates only to the specific material identified at the top of this SDS and may not be valid when the SDS material is used in combination with any other materials or in any process, unless specified in the text. Material users should review the information and recommendations in the specific context of their intended manner of handling, use, processing and storage, including an assessment of the appropriateness of the SDS material in the user's end product, if applicable.

IE / EN